Literature DB >> 25964313

Immunotherapy for glioblastoma: are we finally getting closer?

Michael Lim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25964313      PMCID： PMC4483131          DOI： 10.1093/neuonc/nov070

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  15 in total

1.  A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Authors:  James Schuster; Rose K Lai; Lawrence D Recht; David A Reardon; Nina A Paleologos; Morris D Groves; Maciej M Mrugala; Randy Jensen; Joachim M Baehring; Andrew Sloan; Gary E Archer; Darell D Bigner; Scott Cruickshank; Jennifer A Green; Tibor Keler; Thomas A Davis; Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2015-01-13       Impact factor: 12.300

2.  Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.

Authors:  Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

Review 3.  Brain tumor immunotherapy: seeing the brain in the body.

Authors:  Lois A Lampson
Journal:  Drug Discov Today       Date:  2012-11-27       Impact factor: 7.851

Review 4.  Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of prostate cancer.

Authors:  John J L Jacobs; Chantal Snackey; Albert A Geldof; Dainius Characiejus; R Jeroen A Van Moorselaar; Willem Den Otter
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

Review 5.  Update on vaccines for high-risk melanoma.

Authors:  Sarah A Weiss; Sunandana Chandra; Anna C Pavlick
Journal:  Curr Treat Options Oncol       Date:  2014-06

6.  Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Authors:  John H Sampson; Kenneth D Aldape; Gary E Archer; April Coan; Annick Desjardins; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

7.  Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy.

Authors:  Luis Sanchez-Perez; Carter M Suryadevara; Bryan D Choi; Elizabeth A Reap; John H Sampson
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

Review 8.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

Review 9.  Glioblastoma-derived mechanisms of systemic immunosuppression.

Authors:  Allen Waziri
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

10.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Authors:  Mark R Gilbert; Meihua Wang; Kenneth D Aldape; Roger Stupp; Monika E Hegi; Kurt A Jaeckle; Terri S Armstrong; Jeffrey S Wefel; Minhee Won; Deborah T Blumenthal; Anita Mahajan; Christopher J Schultz; Sara Erridge; Brigitta Baumert; Kristen I Hopkins; Tzahala Tzuk-Shina; Paul D Brown; Arnab Chakravarti; Walter J Curran; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.